Brief: Sio Gene Therapies Announces First Patient Dosed In Clinical Trial Of AXO-AAV-GM2 In Patients With Tay-Sachs And Sandhoff Disease
03/02/2021 12:09
Feb 3 (Reuters) - Sio Gene Therapies Inc SIOX.O :
* SIO GENE THERAPIES ANNOUNCES FIRST PATIENT DOSED IN
CLINICAL
TRIAL OF AXO-AAV-GM2 IN PATIENTS WITH TAY-SACHS AND SANDHOFF
DISEASE (GM2 GANGLIOSIDOSIS)
* SIO GENE THERAPIES INC - EXPECT TO CONTINUE PATIENT
IDENTIFICATION, SCREENING, AND ENROLLMENT IN STAGE 1 OF STUDY
THROUGHOUT 2021
Source text for Eikon: ID:nGNXbRKdsc
Further company coverage: SIOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sio Gene Therapies
See all newsBrief: Sio Gene Therapies Inc - On March 14, Got Notice That Nasdaq Has Determined That Company's Common Stock Will Be Delisted From Nasdaq Capital Market
Brief: Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
Brief: Sio Gene Therapies Inc. Announces Board Approval Of Plan Of Complete Liquidation, Dissolution
Brief: Sio Gene Therapies Announces Second Quarter Financial Results
Brief: Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results